BCL-2 As a Therapeutic Target in Chronic Lymphocytic Leukemia

  Abstract: Venetoclax (formerly ABT-199) was recently approved in the United States for the treatment of patients who have relapsed or refractory chronic lymphocytic leukemia (CLL) […]